Douglas A Steeber
Overview
Explore the profile of Douglas A Steeber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1710
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Belayet J, Beamish S, Rahaman M, Alanani S, Virdi R, Frick D, et al.
J Med Chem
. 2022 Feb;
65(4):3388-3403.
PMID: 35133171
Histone acetylation is a prominent epigenetic modification linked to the memory loss symptoms associated with neurodegenerative disease. The use of existing histone deacetylase inhibitor (HDACi) drugs for treatment is precluded...
2.
Bogoslowski A, Wijeyesinghe S, Lee W, Chen C, Alanani S, Jenne C, et al.
J Immunol
. 2020 Mar;
204(9):2552-2561.
PMID: 32205425
The adaptive immune function of lymph nodes is dependent on constant recirculation of lymphocytes. In this article, we identify neutrophils present in the lymph node at steady state, exhibiting the...
3.
Stealey S, Guo X, Majewski R, Dyble A, Lehman K, Wedemeyer M, et al.
Pharm Dev Technol
. 2019 Nov;
25(2):260-265.
PMID: 31709858
Pectin-based hydrogel microcarriers have shown promise for drug delivery to the colonic region. Microcarriers must remain stable throughout the upper gastrointestinal tract for effective colonic delivery, an issue that traditional...
4.
Forkuo G, Nieman A, Kodali R, Zahn N, Li G, Roni M, et al.
Mol Pharm
. 2019 Oct;
16(11):4756.
PMID: 31633359
No abstract available.
5.
Zahn N, Huber A, Mikulsky B, Stepanski M, Kehoe A, Li G, et al.
Basic Clin Pharmacol Toxicol
. 2019 Jan;
125(1):75-84.
PMID: 30694594
We report a 28-day repeat dose immunotoxicity evaluation of investigational drug MIDD0301, a novel oral asthma drug candidate that targets gamma amino butyric acid type A receptors (GABA R) in...
6.
Forkuo G, Nieman A, Kodali R, Zahn N, Li G, Roni M, et al.
Mol Pharm
. 2018 Mar;
15(5):1766-1777.
PMID: 29578347
We describe lead compound MIDD0301 for the oral treatment of asthma based on previously developed positive allosteric αβγ selective GABA receptor (GABAR) ligands. MIDD0301 relaxed airway smooth muscle at single...
7.
Forkuo G, Nieman A, Yuan N, Kodali R, Yu O, Zahn N, et al.
Mol Pharm
. 2017 Apr;
14(6):2088-2098.
PMID: 28440659
We describe pharmacokinetic and pharmacodynamic properties of two novel oral drug candidates for asthma. Phenolic αβγ GABAR selective compound 1 and acidic αβγ selective GABAR positive allosteric modulator compound 2...
8.
Ku A, Muhitch J, Powers C, Diehl M, Kim M, Fisher D, et al.
Elife
. 2016 Dec;
5.
PMID: 27929373
Myeloid-derived suppressor cells (MDSC) contribute to an immunosuppressive network that drives cancer escape by disabling T cell adaptive immunity. The prevailing view is that MDSC-mediated immunosuppression is restricted to tissues...
9.
Ci S, Huang T, Wen Z, Cui S, Mao S, Steeber D, et al.
Biosens Bioelectron
. 2013 Nov;
54:251-7.
PMID: 24287412
A facile strategy has been developed to fabricate nickel oxide hollow microspheres (NiO-HMSs) through a solvothermal method by using a mixed solvent of ethanol and water with the assistance of...
10.
Grailer J, Steeber D
PLoS One
. 2013 Sep;
8(9):e75390.
PMID: 24066177
Inhibitors of vascular endothelial growth factor and its receptors (VEGFRs) are attractive therapeutic candidates for cancer treatment. One such small molecule VEGFR inhibitor, SU5416, limits angiogenesis in vivo and is...